Investment Thesis
Bioxytran exhibits critical financial distress with negative stockholders equity of -$2.9M, indicating the company is technically insolvent. Revenue has collapsed 22.5% YoY to just $33.6K while operating losses continue to deteriorate, with negative operating cash flow of -$289.5K consuming cash reserves. The company faces imminent solvency risk with minimal liquid assets of $14.5K against $3.1M in liabilities and insufficient operational momentum for turnaround.
Strengths
- Positive gross margin of 30.5% suggests underlying product economics are viable if revenue can scale
- Marginal improvement in net loss of 0.6% and diluted EPS improvement of 33.3% YoY shows minimal stabilization
- Pharmaceutical sector positioning offers potential for value creation if pipeline development succeeds
Risks
- Negative stockholders equity of -$2.9M indicates technical insolvency and existential solvency risk
- Revenue base of $33.6K is critically small and declining, insufficient to support $3.1M liability structure
- Negative operating cash flow of -$289.5K with only $14.5K in cash reserves suggests runway of less than 2 weeks at current burn rate
- Current ratio of 0.00x indicates no ability to meet short-term obligations
- No insider trading activity in 90 days suggests loss of management confidence or dormant operations
Key Metrics to Watch
- Monthly burn rate and cash runway until depletion
- Revenue growth rate and ability to achieve $500K+ quarterly revenue
- Stockholders equity trajectory and path to positive net worth
- Operating cash flow inflection and achievement of positive monthly cash generation
Financial Metrics
Revenue
33.6K
Net Income
-1.6M
EPS (Diluted)
$-0.02
Free Cash Flow
-376.8K
Total Assets
156.3K
Cash
14.5K
Profitability Ratios
Gross Margin
30.5%
Operating Margin
-3,673.4%
Net Margin
-4,761.0%
ROE
N/A
ROA
-1,024.3%
FCF Margin
-1,120.5%
Balance Sheet & Liquidity
Current Ratio
0.00x
Quick Ratio
0.00x
Debt/Equity
N/A
Debt/Assets
1,958.4%
Interest Coverage
-23.74x
Long-term Debt
2.2M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-21T03:16:15.534204 |
Data as of: 2025-09-30 |
Powered by Claude AI